Merck & Co (MRK) DIvidends Date & History

Key Takeaways

• Merck (MRK) offers a current dividend yield of approximately 3%, paid quarterly at $0.85 per share.
• The company has raised its dividend for 15 consecutive years, demonstrating commitment to shareholder returns.
• Payout ratio stands at around 45%, indicating strong sustainability backed by solid earnings and free cash flow (FCF, cash generated after capital expenditures).
• Recent ex-dividend date was March 16, 2026, with payment on April 7, 2026.
• MRK's dividend profile is competitive in the pharmaceutical sector, appealing to income and growth-oriented investors.
• Robust FCF of $18 billion in 2024 supports ongoing dividend payments and potential future increases.

Dividend Overview

Merck (MRK), a leading global pharmaceutical company, maintains a reliable quarterly dividend policy. The current quarterly dividend is $0.85 per share, annualizing to $3.40, which translates to a yield of about 2.97% to 3.04% based on recent stock prices around $112. Payments occur every three months, providing consistent income to shareholders. MRK is positioned as a dividend growth stock rather than a high-yield play, with a history of annual increases that balances reinvestment in R&D with shareholder rewards. This profile suits investors seeking moderate yield with potential for appreciation in the healthcare sector.

Dividend History and Growth

Merck has a long track record of dividend payments spanning over 50 years, with 15 consecutive years of increases as of 2026. The dividend has grown steadily, reflecting the company's strong pipeline of blockbuster drugs like Keytruda. Recent hikes include a raise to $0.85 per share announced in January 2026 for the second quarter. No cuts have occurred in decades, underscoring a conservative yet progressive long-term strategy focused on sustainable growth amid patent cycles and innovation.

Dividend Sustainability and Payout Ratio

MRK's dividend sustainability is robust, with a payout ratio of approximately 44.8% to 45.5% of earnings, leaving ample room for growth and reinvestment. Earnings comfortably cover dividends, and FCF provides even stronger support, with a free cash flow payout ratio well above 1x coverage. The company's 2024 FCF reached $18.1 billion, bolstered by operational efficiency and a manageable debt-to-FCF ratio. Overall financial health, including solid liquidity, positions MRK to maintain and potentially grow its dividend through economic cycles.

Dividend Compared to Industry Peers

In the pharmaceutical industry, MRK's ~3% yield is competitive. Peers like Pfizer (PFE) offer higher yields around 6%, driven by post-COVID dynamics, while Johnson & Johnson (JNJ) yields about 2.2%. AbbVie (ABBV) provides 3.4%, and Bristol-Myers Squibb (BMY) around 4.3%. MRK stands out for its balance of yield, growth streak, and lower payout ratio compared to higher-yield peers, making it attractive for those prioritizing stability over maximum income.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. It excels at identifying dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener today to enhance your investment strategy.

Is This Stock Attractive for Dividend Investors?

Merck (MRK) appeals to dividend growth investors who value consistent raises over 15 years paired with a safe 3% yield and low payout ratio. Its pharmaceutical leadership provides defensive qualities, making it suitable for conservative, long-term holders seeking healthcare exposure amid aging populations and innovation. Income investors may find the yield solid but not ultra-high, while those prioritizing total returns benefit from FCF strength funding R&D and buybacks. However, patent expirations pose risks, so it fits portfolios balancing growth and income without excessive volatility. Balanced investors appreciate MRK's track record, but high-yield seekers might look to peers like PFE.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations